International Association for the Study of Lung Cancer (IASLC) 2022 World Conference on Lung Cancer (WCLC 2022)

Smoking cessation intervention during lung screening may encourage quitting

Roshini Claire Anthony, 20221205150001

A smoking cessation intervention, introduced as part of lung health screening, may encourage quitting in about 30 percent of smokers, results of the UK-based YESS* trial showed.

NADIM II suggests PFS, OS benefits of nivolumab + chemo in resectable NSCLC

Roshini Claire Anthony, 20221102180001

Adding nivolumab to paclitaxel-carboplatin chemotherapy in the neoadjuvant setting boosted progression-free survival (PFS) and overall survival (OS) in patients with resectable stage IIIA–B non-small cell lung cancer (NSCLC), according to results of the phase II NADIM II trial from Spain.

Atezolizumab may improve OS in resected NSCLC with PD-L1 ≥1 percent

Does atezolizumab improve OS in patients with resected NSCLC and PD-L1 ≥1 percent?

Roshini Claire Anthony, 20221016110001

The first interim analysis of the phase III IMpower010 trial suggests an overall survival (OS) benefit with atezolizumab compared with best supportive care (BSC) in patients with resected non-small cell lung cancer (NSCLC) with PD-L1* tumour cell expression ≥1 percent.

Pembrolizumab-based regimen continues to show favourable signals for ES-SCLC

Audrey Abella, 20221014100000

In the long-term follow-up of the KEYNOTE-604 study, the combination regimen comprising pembrolizumab and etoposide/platinum (EP*) continued to demonstrate survival benefit as first-line therapy for patients with previously untreated extensive-stage small cell lung cancer (ES-SCLC).

Sugemalimab for stage III NSCLC: Efficacy, safety signals sustained in final PFS analysis

Audrey Abella, 20221007100000

In the final progression-free survival (PFS) analysis of the GEMSTONE-301 study, sugemalimab demonstrated sustained efficacy and safety as consolidation treatment for individuals with unresectable stage III non-small cell lung cancer (NSCLC) whose disease had not progressed following either concurrent chemoradiotherapy (cCRT) or sequential CRT (sCRT).